Regeneration carries the idea of regrowing partially or completely a missing organ. Repair, on the other hand, allows restoring the function of an existing but failing organ. The recognition that human lungs can both repair and regenerate is quite novel, the concept has not been widely used to treat patients. We present evidence that the human adult lung does repair and regenerate and introduce different ways to harness this power. Various types of lung stem cells are capable of proliferating and differentiating upon injury driving the repair/regeneration process. Injury models, primarily in mice, combined with lineage tracing studies, have allowed the identification of these important cells. Some of these cells, such as basal cells, broncho-alveolar stem cells, and alveolar type 2 cells, rely on fibroblast growth factor (FGF) signaling for their survival, proliferation and/or differentiation. While preclinical studies have shown the therapeutic benefits of FGFs, a recent clinical trial for acute respiratory distress syndrome (ARDS) using intravenous injection of FGF7 did not report the expected beneficial effects. We discuss the potential reasons for these negative results and propose the rationale for new approaches for future clinical trials, such as delivery of FGFs to the damaged lungs through efficient inhalation systems, which may be more promising than systemic exposure to FGFs. While this change in the administration route presents a challenge, the therapeutic promises displayed by FGFs are worth the effort.
the nail bed can, upon sectioning of the finger's tip where the third phalange is located, assemble to form a functional structure, called the blastema. Such a structure contributes to the missing tissue and drives the regeneration process, allowing regrowth of the missing phalange [3] . However, proper regrowth by the blastema of the surrounding vascular, muscle, and nervous tissue is not evident. It is essential to note that the capacity to regrow our fingertips appears to be restricted mostly to early infancy. In general, adults do not display this regenerative capacity, and one of the underlying reasons could be that the stem cells responsible for the regrowth are either no longer functional or/and the stromal niche, which is a critical component maintaining the stem cell pool, is impaired. Modern science has added to the list of organs or tissues that harbor significant regenerative power. These include the skin, gut, and blood. Until recently, it was believed that organs such as the brain and the lung did not have regenerative capacity.
Can human lungs regenerate?
The recognition that human lungs can regenerate is quite novel. While it was previously known that rodents' lungs could regenerate after pneumonectomy [4] , no reports were available to show that this was also the case in humans. In mice, the removal of the left lung leads to the rapid compensatory growth of the right lung, thereby allowing the overall lung function to reach near baseline levels (preoperative values) within three weeks [5] . Using FDG-PET (positron-emission tomography) and micro-CT (computerized tomography) scanning to investigate metabolic activity during compensatory lung growth following pneumonectomy, it was shown that after left pneumonectomy, the right lung progressively enlarged over the first three weeks [6] . The accessory (also called cardiac) lobe displayed the greatest size increase. PET/CT imaging was used to monitor metabolic activity within the individual lobes. In the cardiac lobe, 18FDG uptake (glucose analog tracer 2-deoxy-2-[18F]fluoro-d-glucose) was significantly increased in the accessory lobe at day 14 relative to preoperative values (P < 0.05). Interestingly, the 18FDG uptake in the other three right lobes (cranial, medial, and caudal) did not significantly change at any time point. Thus, compensatory growth after murine pneumonectomy occurs mostly in the accessory lobe.
After these studies in mice, a seminal paper by Butler and colleagues was published [7] , demonstrating that, indeed, compensatory lung growth is also possible in humans. They reported the case of a 33-year-old woman diagnosed with lung adenocarcinoma in 1995. Her treatment involved a right-sided pneumonectomy to remove the tumor. As expected, the removal of the right lung led to a severe reduction in her lung function.
However, follow-up examinations over the next 15 years indicated that she progressively recovered almost full lung capacity. This patient had an initial FEV1 (forced expiratory volume, an essential measure of pulmonary function) of 35% and FVC (forced vital capacity, defined as the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible) of 49% after pneumonectomy.
During the 15 years post-operation, a progressive, constant improvement was observed. The patient's spirometry resulted in a final FEV1 of 60% and FVC of 73% (interestingly, based on aging alone, during these 15 years a 10% decline of her lung function should have been observed). Annual surveillance CT scans indicated that the size of her remaining left lung was more substantial than before. Estimation of acinar-airway dimensions by magnetic resonance imaging suggested an increase in the number of alveoli, rather than the enlargement of preexisting alveoli. Following this evidence that the human lung is capable of regeneration, a critical question remained: how are we going to integrate this vital function in the treatment of lung disease. From a clinical point of view, this relatively new concept is still not widely used to design innovative therapies to treat patients.
Repairing damaged lungs ex vivo may offer a solution for the lack of suitable lungs for transplants One aspect linked to the newly accepted concept that human lungs can regenerate is that part of this regeneration process should also involve a tonic repair process of the existing but failing lung. A recent publication has investigated the repair potential of low-quality (damaged) donor lungs, which are usually considered non-suitable for transplantation [8] . Lung transplantation is considered the last therapeutic option for devastating end-stage lung disease. Many progresses have been made to enhance posttransplant survival. These include inducing immune tolerance and preventing infections. However, a key aspect of successful lung transplantation is the quality of the donor lung to prevent primary graft dysfunction [9] . One crucial challenge to improve the quality of the donor lungs has been the time window available to treat the lungs after removal from the deceased donors. A recent report described an elegant method to maintain a fully functional lung outside the body for over 36-56 h [8] . An advanced support system, involving a relatively old technique called cross-circulation, allowed the lungs previously damaged by ischemia/reperfusion to functionally recover, making them acceptable for lung transplants. Cross-circulation was a surgical procedure frequently used in the 1950s to allow the exchange of blood flow between two patients. Applied in the context of this study, this approach, which made use of the swine model, permitted long-term support of the lungs outside the body. A first priority in this study was to provide the right temperature to the explanted lung in order to mimic the conditions existing in the chest cavity. To that end, the researchers developed innovative solutions such as a humidification system with ambient temperature control and a re-circulating warm water organ basin. This system also prevented the outer surface of the lung from drying out, thereby keeping the integrity of the lung. They also improved the blood flow into and out of the lungs during cross-circulation by developing new components and techniques allowing height and hydrostatic pressure adjustments and feedback-regulated pressure-controlled flow. In addition to delivering to the lungs critical systemic and metabolic factors, this approach allowed therapeutic interventions, which aimed to restore lung function. Stem cells were used to replace defective cells with new therapeutic cells derived from the transplant recipient. Drug cocktails were also applied to improve the repair process. The authors also established image-guided techniques for the delivery of drugs and cells in specific regions of the lung without the need for repeated biopsies.
Balancing lung regeneration and lung function: the welcome use of extracellular corporeal membrane oxygenation (ECMO)
One particular challenge, when faced with severe lung diseases such as pneumonia, is that the lungs undergo drastic remodeling, with massive infiltration of immune cells in the parenchyma associated with large areas of alveolar destruction (emphysema), as well as fibrotic foci. It is clear that keeping the lungs functioning in these conditions is difficult, and may not be compatible with an efficient repair process. The use of extracellular corporeal membrane oxygenation (ECMO) in this context has proven to be efficient for patients undergoing massive lung failure [10] . In ECMO, blood from the patient is drawn through a catheter and run through a device that adds oxygen and removes the carbon dioxide and then returns the blood to the patient. During this time, the patient is exposed to a low-level ventilator, thereby allowing the lungs to move. This setting prevents the deleterious mechanical stress induced by a high-level ventilator and high oxygen concentration (the standard therapy for ARDS, when the patient is responsive). This delicate technique, which has been defined as the equivalent of dialysis for the lung, calls for the intervention of a multidisciplinary team, and bypasses the use of the lungs, allowing them to "rest" while the endogenous process of repair is taking place. Patients remain typically on ECMO for ten days, but this time can be prolonged based on their overall health conditions. Again, the critical process at work to repair/regenerate the lungs in both in vitro and in vivo settings is the fact that stem cells are present in the adult lung. The next section will describe the different types of stem cells present in the adult lung, which are key to the repair process.
Key adult endogenous stem cells needed for regeneration
As the adult lung is relatively quiescent compared to other organs, such as the skin or the gut, it has been challenging to detect proliferative cells that could be playing the role of stem cells. The use of injury models, primarily in mice, combined with lineage tracing experiments, has allowed the identification of these cells. It has been reported that most of the epithelial cells can proliferate and differentiate into different epithelial cells following injury. These include, in the conducting airway, the basal cells [11] , club cells [12] [13] [14] , and variant of club cells [13, 15] , at the exception of the ciliated cells. In the respiratory airway, these cells include the alveolar type 2 (AT2) cells [16, 17] , the alveolar type 1 (AT1) cells [18, 19] , the bronchoalveolar stem cells (BASCs) [20] , and the lineage negative epithelial progenitor (LNEP) cells [21] . Fig.1 shows the position of these cells along the proximal-distal axis of the human lung. Table 1 summarizes what is known about these cells (for an extensive review see [22] ). It is important to mention that while the human equivalent of these mouse epithelial stem cells have been identified, it is difficult to functionally validate these cells in human in vivo. Most of the approaches to test the property of these stem cells (self-renewal and differentiation) have been carried out using organoids (mixture of epithelial "stem" cells and mesenchymal cells grown in Matrigel, see [23] ). There is therefore no direct testing of their stem cell capabilities by transplanting these cells in damaged human lungs with the goal to investigate their capacity to integrate into injured areas as well as proliferate and differentiate. Therefore, this important functional validation for these cells in human is still missing.
Some adult stem cells rely on Fgf signaling for their survival, proliferation and/or differentiation
Fibroblast growth factors (Fgfs) belong to a large superfamily of signaling molecules. Among them, the members of the Fgf7 subgroup, consisting of Fgf-1, -3, -7, -10 and -22, act via the Fgf receptor (Fgfr) 2b expressed mostly by epithelial cells [24] . Fgf signaling is mediated via the activation of PI3K-and MAPK-signaling pathways and/or activation of phospholipase C γ (Plc-γ). Fgfr2b-signaling leads to the growth, survival, and differentiation of epithelial cells. Fgf10/Fgfr2b signaling is critical for 
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Hopx, Aqp5, Pdpn AT1, AT2 Hopx-CreERT2 [18, 19] murine lung development, while Fgf7 is dispensable [25] [26] [27] . There is strong evidence that Fgf signaling is key to control the formation of different epithelial lung lineages during ontogenesis. Fgf10, for example, elicits, in a dosedependent manner, the formation of the alveolar epithelial lineage. During early development, Fgf10 has been previously described to maintain the undifferentiated status of the stem cells expressing both (sex determining region Y)-box9 (Sox9) and the inhibitor of DNA binding 2 (Id2) in the distal lung epithelium. Upon inhibition of Fgf10 activity, these cells acquire the expression of Sox2, a marker of the bronchiolar lineage [28] . The use of Id2-CreERT2 driver mice to lineage-trace these cells demonstrated that they give rise to all the cells in the alveolar and bronchiolar lineages. Our results also indicated that Fgf10 could play an important role not only in the proliferation but also in the differentiation of the epithelial progenitor cells toward the AT2 lineage [28] . In particular, we reported that there is an unbalanced alveolar population as the percentile of AT2 cells is decreased while the percentile of AT1 cells is increased. We also show that the expression of the AT2 cell signature is decreased in Fgf10 heterozygous AT2 cells [29] . Interestingly, Fgf10 hypomorphic lungs, displaying 20% of the normal Fgf10 expression present in wild type (WT) lungs, also show a pronounced defect in AT2 cells, further supporting a role for Fgf10 in AT2 lineage formation [29] . The role of Fgf10 on adult AT2 cells is therefore particularly promising. Interestingly, Fgf10 overexpression in the adult lung leads to BASC amplification [30] . It is possible that Fgf10 could directly act on BASCs, as evidenced by single-cell RNA sequencing showing that Fgfr2 expression is enriched in these cells [20, 31] . Lineage tracing of BASCs, combined with single cell RNA-seq in the context of either naphthalene or bleomycin injury, should allow the identification of the different relevant pathways activated in these cells during the repair process. Basal cells can be specifically labeled using the nerve growth factor receptor (Ngfr). This gene was drastically reduced in the Fgf10 hypomorphic lungs [29] , suggesting that Fgf10 was instrumental for the formation of the basal cells. Indeed, the blockade of Fgfr2b ligands, or the activation of Fgf10 signaling, led to the almost complete reduction of basal cells, or their expansion, respectively [30, 32] .
Adult epithelial stem cells exist in the context of specific stromal niches Different stromal niches are associated with various types of epithelial stem cells in the distal lung (Fig. 2) . Previously, we proposed that the airway smooth muscle cells (ASMCs) represent a niche for the variant of club cells. In this model, following injury, the ASMCs respond to Wnt signaling from the epithelium and start expressing Fgf10, which will subsequently act on the variant of club cells present in the epithelium, thus facilitating their proliferation [30, 32] . We propose that this model should be revisited, as many other cell types are intertwined with the ASMCs, such as glioma-associated oncogene homolog 1 (Gli1)-positive cells [33] . It has been proposed that upon injury, sonic hedgehog (Shh) expression from the epithelium is decreased, thereby allowing the expansion of the target cells (Gli1-positive). The role of these cells in the context of repair is not clear. In regard to the other types of stem cells present in the distal region of the lung, the BASCs interact with still to be defined stromal cells, while the LNEP interact with stem cell antigen (Sca) 1-positive resident stromal cells. Finally, the AT2 cells interact with lipofibroblasts (LIFs). Interestingly, all these stromal niches express Fgf10, suggesting that this growth factor could be crucial for the repair process. Lung stromal cells expressing platelet-derived growth factor receptor α (PDGFRα) are instrumental for AT2 cell growth in vitro using alveolospheres. Lineage-labeled AT2 cells isolated by FACS were mixed with primary PDGFRα-positive lung stromal cells and placed in 3D culture (Matrigel). In these conditions, these AT2 cells gave rise to self-renewing "alveolospheres," which contained both AT2s and cells expressing multiple AT1 markers [16] . This stromal population included LIFs, lipid droplet containing cells that expressed adipose related protein (ADRP), and PDGFRα [34] [35] [36] . LIF normally reside close to AT2s. LIF may therefore constitute a stromal niche for AT2 stem cells in the murine lung. A similar dynamic exists between AT2 and mesenchymal cells in the human lung. More recently, the Morrisey laboratory showed that these AT2 supportive cells co-express axis inhibition protein 2 (Axin2), PDGFRα, and Fgf7 [37] . These cells may be different from the PDGFRα-positive Fgf10-positive LIFs, which our research group is focusing on. LIFs are lipid-containing alveolar interstitial fibroblasts. These cells are becoming increasingly recognized as an important component of the AT2 stem cell niche in the rodent lung. Although the function of LIFs was initially described to assist AT2 cells in surfactant production, recent evidence suggests that these cells are also crucial for survival and growth of epithelial stem cells. We have recently investigated their cellular origin, as well as the pathways controlling their formation, during lung development.
A population of lipid-droplet-containing stromal cells emerges in the developing mouse lung between embryonic day 15.5 and E16.5 [34] . This is associated with the upregulation, in the lung mesenchyme, of three important genes involved in lipogenesis, namely, Adrp (a marker of mature LIFs), peroxisome proliferator-activated receptor γ (Pparγ) (master switch of lipogenesis) and Fgf10 (previously shown to identify a subpopulation of lipofibroblast progenitors). In addition, while only a subpopulation of total embryonic LIFs derives from Fgf10 pos progenitor cells, the knockdown of Fgfr2b ligand activity in vivo, as well as the reduction in Fgf10 expression, led to a global reduction in the expression levels of LIF markers at E18.5. The analysis of Fgfr1b knockouts, as well as mutants with conditional partial inactivation of Fgfr2b in the lung mesenchyme, shows that both receptors are involved in LIFs formation, suggesting a possible compensation between these two receptors. We also reported the expression of FGF10 and ADRP in human fetal lungs over time. We proposed that Fgf10 signaling plays a key role in the formation of LIFs during late lung development. One important pathological process to consider is what is happening to the stromal niche when the corresponding epithelial stem cells are damaged, either acutely or chronically. In the context of acute damage to the AT2 cells using bleomycin (resulting in lung fibrosis), we previously reported that the LIFs give rise to activated myofibroblasts (MYFs) [38] . We also reported, using in vivo lineage tracing tools, that lineage-labeled activated MYFs give rise to LIFs during the resolution of fibrosis [38] . Please see a comprehensive review of the role of mesenchymal stem cells in fibrosis formation [39] .
FGF10 deficiency is associated with human lung disease
Two human syndromes, namely, the aplasia of lacrimal and salivary glands (ALSG) and the lacrimo-auriculo-dentodigital syndrome (LADD), are associated with heterozygous mutations in the human FGF10 or FGFR2B genes, respectively [40, 41] . In particular, IVC, FEV1, and the corresponding FEV1/IVC ratio were significantly lower in patients with loss of FGF10 functional heterozygosity compared to both non-carrier siblings and predicted reference values [42] . These data are consistent with the diagnostic of chronic obstructive pulmonary disease. In humans, exposure to inflammation is known to increase the risk of developing broncho-pulmonary dysplasia (BPD) [43] . BPD develops in babies born prematurely and is characterized by impaired alveolar development. Consistent with the presence of high inflammation in the lungs of babies with BPD, it has been demonstrated that interactions between nuclear factor kB (NF-kB), specificity protein 1 (Sp1), and Sp3 led to inhibition of Fgf10 expression [44] . Fgf10 inhibition is mediated by activation of Toll-like receptors 2 and 4 (Tlr2 or Tlr4), and a decrease in FGF10 concentration is found in lung samples from children with BPD [45] . The molecular mechanisms linking inflammatory signaling and FGF10, an important developmental gene that might play a role in BPD pathogenesis, are still elusive.
Pre-clinical (rodent) models indicating that recombinant FGF10 can be used to repair and regenerate human lungs
We previously reported that canonical wingless-related integration site (Wnt)-signaling works downstream of Fgf signaling [28, 46, 47] . Interestingly, exposure to bleomycin in mice displaying an epithelial-specific deletion of βcatenin-signaling (β-catenin is downstream of both Fgfand Wnt-signaling) led to increased fibrosis [48] . In the mouse model, previous studies focused primarily on the beneficial effect of treatment with Palifermin, a truncated form of keratinocyte growth factor (KGF, also known as FGF-7) [49, 50] . While KGF demonstrated an apparent protective effect, genetic Fgf10 overexpression postbleomycin injury resulted in increased survival, as well as prevention and accelerated resolution of lung fibrosis in mice [51] . Interestingly, established IPF therapies which target tyrosine kinases (e.g., nintedanib), would also inhibit FGF signaling, and this may lead to detrimental effects. There is, therefore, an urgent need to define the role of endogenous FGF signaling in IPF.
Because of the beneficial effects of exogenous Fgfr2b ligands on lung repair, we hypothesized that endogenous Fgfr2b ligands play an essential role in repair following bleomycin injury. However, we found that the expression of Fgfr2b ligands and receptors were decreased after bleomycin injury in wild type mice [52] . In the same study, we reported that inhibition of the activity of endogenous Fgfr2b ligands during bleomycin-induced lung injury did not lead to significantly increased fibrosis or decreased survival. These results do not negate the potential benefit of exogenously stimulating developmental pathways to protect against lung fibrosis.
Fgf10 is also involved in the regeneration of the bronchial lung epithelium after naphthalene injury [30] . We recently published that Fgf10-Hippo epithelialmesenchymal crosstalk maintains and recruits lung basal stem cells in the conducting airways [32] . In this paper, we showed that, while transient Fgf10 expression by ASMCs is critical for proper airway epithelial regeneration in response to injury, sustained Fgf10 secretion by the ASMC niche, in response to chronic integrin-like kinase (Ilk)/ Hippo inactivation, results in pathological changes in airway architecture. Fgf10/Fgfr2b signaling may, therefore, be an interesting therapeutic target to treat chronic lung diseases.
Influenza virus (IV)-mediated pneumonia often leads to severe damage to the lung epithelium and impairment of respiratory functions. We have previously described the importance of Fgf signaling in enhancing stem/progenitor cell-mediated regenerative responses. Importantly, we have reported that a highly pathogenic IV preferentially infects an epithelial cell subset characterized by high proliferative capacity and defined by EpCam high CD24 low integrin(α6) high . These cells are also positive for Sca1 and are highly enriched in the lung stem cell pool previously characterized by the signature integrin (β4) + CD200 + . We used 3-dimensional organoid cultures derived from these epithelial stem/progenitor cells (EpiSPC), and in vivo infection models including transgenic mice, to show that their proliferation and the maintenance of the epithelial barrier after IV-induced injury required Fgfr2b signaling. IV-infected EpiSPC displayed decreased renewal capacity due to the IV-induced blockade of β-catenin-dependent Fgfr2b signaling. Therapeutic application of FGF10 intratracheally led to increased recruitment of non-infected EpiSPC for tissue regeneration and was associated with enhanced proliferative potential, restoration of alveolar barrier function, and increased survival following IV pneumonia [53] . Furthermore, Fgf10 delivery to the distal lung may represent a putative therapy to enhance regeneration in the context of acute respiratory distress.
FGF7 clinical trial for acute respiratory distress syndrome (ARDS): lessons learnt for future clinical trials
Mortality linked to ARDS remains unacceptably high, underscoring the fact that no efficient pharmacological therapy exists despite intense basic and clinical research. FGF7 seemed initially to be perfectly suited for ARDS treatment. Various pre-clinical studies in animals demonstrated its efficacy in enhancing the repair mechanisms following experimental acute lung injury [54] . Interestingly, FGF7 expression in human lungs is suppressed in early ARDS [55] . In addition, it was shown that FGF7 enhances alveolar epithelial sodium ion (Na + ) transport processes, thereby allowing the efficient clearance of alveolar edema [56] , which is required for the survival of patients with ARDS. Moreover, in a recent clinical trial, 36 healthy volunteers received intravenously-administered FGF7 (60 mg/kg per day), or placebo for three days before inhalation of lipopolysaccharide (LPS) to trigger acute lung injury [57] . The analysis of the bronchoalveolar lavage fluid samples of these patients collected 6 h after LPS inhalation indicated that pre-treatment with FGF7 increased the concentrations of anti-inflammatory cytokines and markers of alveolar epithelial type II cell proliferation. These data suggest that systemic exposure to FGF7 is well tolerated and, most importantly, has an effect on the alveolar epithelium. Interestingly, FGF7 was also efficient in treating patients with oral mucositis as a consequence of radiotherapy and chemotherapy [58] . This was likely the rationale to use the same concentration, frequency, and duration of FGF7 treatment in a recent clinical trial aiming to characterize, in patients with ARDS, the impact of intravenously-administered FGF7 [59] . In the prospective, double-blind, randomized, allocation-concealed, placebo-controlled phase 2 KARE trial, 60 patients with moderate-to-severe ARDS were included. The oxygenation index at day 7 was assessed as the primary outcome. This readout is a reliable predictor of therapy success in ARDS, as it takes into consideration both gas exchange and respiratory mechanics. The study demonstrated that FGF7 did not ameliorate any of the primary clinical and physiologic outcomes assessed. Even though the trial was not properly designed to evaluate secondary readouts such as the duration of ventilation, mortality, or the length of intensive-care unit stay, the results do suggest that these secondary outcomes became worse in the experimental group receiving FGF7. The authors concluded that FGF7 should not be used for the treatment of ARDS patients.
It is to be noted that in the context of this study, conclusions about the negative impact of FGF7 on the clinical outcomes are difficult to assess as the trial was not designed to assess the secondary readouts and also because the mortality in the placebo group was surprisingly lower than expected for this patient cohort. The lack of effects of FGF7 on ARDS patients could be due to different reasons. First, there is no evidence that the dose and route of FGF7 administration used in this trial were optimal to act on the damaged alveolar epithelium. In addition, in the human LPS inhalation clinical study [57] , the alveolar epithelium was healthy at the time of FGF7 treatment, while the diseased lungs in ARDS patients likely displayed both under-ventilated and non-ventilated lung areas. This may have had a negative impact in the context of FGF7 treatment as the damaged areas are likely less perfused than healthy regions of the lung. It is therefore possible that the level of FGF7 in these areas was too low to trigger a clear biological effect within the time frame of the trial. In addition, systemic concentrations of FGF7 may have been too high, triggering some of the negative effects observed during the trial.
It is worth to mention that in most animal pre-clinical studies assessing the effect of FGF7 in acute lung injury, the growth factor was supplied directly to the lungs either by inhalation or instillation. The translation to the human situation may not be easy; even though drug inhalation for patients with ARDS might be useful when targeting macrophages [60] , it is not clear whether poorly or nonventilated areas can be effectively reached. Failure to do so could be the underlying cause behind the failure in clinical trials for ARDS of various promising pharmacological treatments. In the future, optimizing delivery protocols to deliver efficiently the drugs at the alveolar level will be crucial.
Looking toward the future: rationale to use FGF10 instead of FGF7 for clinical trials While FGF7 was historically thought to be a potent FGF to enhance the repair/regeneration process, FGF10 has emerged as a more relevant growth factor for clinical use for different reasons. First, evidence in mice shows that Fgf10, and not Fgf7, is the growth factor used by the lung for its development. Fgf10 inactivation leads to lung agenesis, while Fgf7 null mice have no distinct lung phenotype [26, 62] . Second, Fgf10 is the endogenous growth factor used by the lung to act on key epithelial stem cells (basal cells, a variant of club cells, epiSPC and AT2) for the regeneration process. Third, even though FGF7 and FGF10 can act via the same receptor, they elicit different biological responses (proliferation vs. migration, respectively). The molecular bases for this difference were first reported by our research group [63] . Fourth, FGF10 does not induce directly epithelial proliferation but works by modulating cell-cell and cell-extracellular matrix adhesion [28] . Therefore, FGF10 may be safer to use compared to FGF7 in the clinical context. Indeed, our recently published data indicate that in early development, the transcription of G protein-coupled receptor class C group 5 member A (Gprc5a), a gene coding a G protein-coupled receptor acting as an anti-oncogene, is induced by Fgf10. Inactivation of Gprc5a in mice leads to lung adenocarcinoma [64] . So Fgf10, via the induction of Gprc5a, as well as other genes previously described in Jones et al. [28] may prevent cancer formation.
In conclusion, with the recent evidence that the human lung both repairs and regenerates and with the characterization of the crucial corresponding stem cells, fibroblast growth factors are ideally suited to act on these cells to promote repair and regeneration. In the future, clinical trials must be tailored to allow local delivery to the damaged lungs.
